The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (interstitial lung disease/ILD)

Publications

Bolaki M, Karagiannis K, Bertsias G, Mitrouska I, Tzanakis N, Antoniou KM

New respiratory symptoms and lung imaging findings in a woman with polymyositis.

Breathe (Sheffield, England) 2018 Jun;14;e34-e39 — 2018 Jun — e34-e39

Sato K, Nagai T, Izumi T, Ohmine K, Ozaki K, Muroi K, Ozawa K

Rituximab-induced interstitial pneumonia due to CD8-positive T cell infiltration.

Acta haematologica 2012;128;107-9 — 2012 — 107-9

Arulkumaran N, Suleman R, Cecconi M, Kiely P, Chua F

Rituximab associated pneumonitis in antineutrophil cytoplasmic antibody-associated vasculitis.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2012 Jan;18;39-41 — 2012 Jan — 39-41

Kang HJ, Park JS, Kim DW, Lee J, Jeong YJ, Choi SM, Lee SM, Yang SC, Yoo CG, Kim YW, Han SK, Yim JJ

Adverse pulmonary reactions associated with the use of monoclonal antibodies in cancer patients.

Respiratory medicine 2012 Mar;106;443-50 — 2012 Mar — 443-50

Huang YC, Liu CJ, Liu CY, Pai JT, Hong YC, Teng HW, Hsiao LT, Chao TC, Gau JP, Liu JH, Hsu HC, Chiou TJ, Chen PM, Yu YB, Tzeng CH

Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma.

Annals of hematology 2011 Oct;90;1145-51 — 2011 Oct — 1145-51

Tonelli AR, Lottenberg R, Allan RW, Sriram PS

Rituximab-induced hypersensitivity pneumonitis.

Respiration; international review of thoracic diseases 2009;78;225-9 — 2009 — 225-9

Heresi GA, Farver CF, Stoller JK

Interstitial pneumonitis and alveolar hemorrhage complicating use of rituximab: case report and review of the literature.

Respiration; international review of thoracic diseases 2008;76;449-53 — 2008 — 449-53

Swords R, Power D, Fay M, O'Donnell R, Murphy PT

Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP).

American journal of hematology 2004 Sep;77;103-4 — 2004 Sep — 103-4

Giagounidis AA, Anhuf J, Schneider P, Germing U, Söhngen D, Quabeck K, Aul C

Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study.

European journal of haematology 2002 Aug;69;95-100 — 2002 Aug — 95-100